|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||26.00 - 26.00|
|52-week range||26.00 - 26.00|
|Beta (5Y monthly)||0.13|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
What happened AnaptysBio (NASDAQ: ANAB) closed more than 10% higher on Friday. This followed news that a drug the company partnered on has received a positive opinion from an important multinational health agency.
On Tuesday, AnaptysBio (NASDAQ: ANAB) traded down nearly 10% at one point, before recovering to end the day 2.5% higher. There wasn't any direct news driving such sentiments; rather, it seems other factors were at play. AnaptysBio is a clinical-stage biotech that concentrates on immunology therapies -- currently a hot area of development in the healthcare world.
AnaptysBio (NASDAQ: ANAB) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly. J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. Rama is basing his enthusiasm on the company's upcoming official data release for its phase 2 clinical trial of imsidolimab.